177 related articles for article (PubMed ID: 24042256)
1. Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk.
Okada S; Morimoto T; Ogawa H; Sakuma M; Soejima H; Nakayama M; Sugiyama S; Jinnouchi H; Waki M; Doi N; Horii M; Kawata H; Somekawa S; Soeda T; Uemura S; Saito Y;
Circ J; 2013; 77(12):3023-8. PubMed ID: 24042256
[TBL] [Abstract][Full Text] [Related]
2. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
3. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Saito Y; Okada S; Ogawa H; Soejima H; Sakuma M; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Morimoto T;
Circulation; 2017 Feb; 135(7):659-670. PubMed ID: 27881565
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Sugawara M; Goto Y; Yamazaki T; Teramoto T; Oikawa S; Shimada K; Uchiyama S; Ando K; Ishizuka N; Murata M; Yokoyama K; Uemura Y; Ikeda Y;
Am J Cardiovasc Drugs; 2019 Jun; 19(3):299-311. PubMed ID: 30565155
[TBL] [Abstract][Full Text] [Related]
5. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.
Rothwell PM; Cook NR; Gaziano JM; Price JF; Belch JFF; Roncaglioni MC; Morimoto T; Mehta Z
Lancet; 2018 Aug; 392(10145):387-399. PubMed ID: 30017552
[TBL] [Abstract][Full Text] [Related]
6. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Ogawa H; Nakayama M; Morimoto T; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Saito Y;
JAMA; 2008 Nov; 300(18):2134-41. PubMed ID: 18997198
[TBL] [Abstract][Full Text] [Related]
7. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Gaziano JM; Brotons C; Coppolecchia R; Cricelli C; Darius H; Gorelick PB; Howard G; Pearson TA; Rothwell PM; Ruilope LM; Tendera M; Tognoni G;
Lancet; 2018 Sep; 392(10152):1036-1046. PubMed ID: 30158069
[TBL] [Abstract][Full Text] [Related]
8. Proteinuria is independently associated with the incidence of primary cardiovascular events in diabetic patients.
Soejima H; Ogawa H; Morimoto T; Okada S; Matsumoto C; Nakayama M; Masuda I; Jinnouchi H; Waki M; Saito Y;
J Cardiol; 2020 Apr; 75(4):387-393. PubMed ID: 31564388
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.
Teramoto T; Shimada K; Uchiyama S; Sugawara M; Goto Y; Yamada N; Oikawa S; Ando K; Ishizuka N; Yamazaki T; Yokoyama K; Murata M; Ikeda Y
Am Heart J; 2010 Mar; 159(3):361-369.e4. PubMed ID: 20211296
[TBL] [Abstract][Full Text] [Related]
10. Review of an article: aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association (ADA), a scientific statement of the American Heart Association(AHA), and an expert consensus document of the American College of Cardiology Foundation (ACCF). Diabetes Care, 33:6; June 2010; 1395-1402.
Gilpin VL; ; ;
J Vasc Nurs; 2010 Dec; 28(4):154-5. PubMed ID: 21074118
[No Abstract] [Full Text] [Related]
11. Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial.
Okada S; Morimoto T; Ogawa H; Kanauchi M; Nakayama M; Uemura S; Doi N; Jinnouchi H; Waki M; Soejima H; Sakuma M; Saito Y;
Diabetes Care; 2011 Jun; 34(6):1277-83. PubMed ID: 21515838
[TBL] [Abstract][Full Text] [Related]
12. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Sacco M; Pellegrini F; Roncaglioni MC; Avanzini F; Tognoni G; Nicolucci A;
Diabetes Care; 2003 Dec; 26(12):3264-72. PubMed ID: 14633812
[TBL] [Abstract][Full Text] [Related]
13. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.
Steinhubl SR; Bhatt DL; Brennan DM; Montalescot G; Hankey GJ; Eikelboom JW; Berger PB; Topol EJ;
Ann Intern Med; 2009 Mar; 150(6):379-86. PubMed ID: 19293071
[TBL] [Abstract][Full Text] [Related]
14. Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly.
Patel NJ; Baliga RR
Curr Cardiol Rep; 2020 May; 22(7):48. PubMed ID: 32472363
[TBL] [Abstract][Full Text] [Related]
15. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U
Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin.
Simpson SH; Abdelmoneim AS; Omran D; Featherstone TR
Am J Med; 2014 Jan; 127(1):95.e1-9. PubMed ID: 24384107
[TBL] [Abstract][Full Text] [Related]
18. Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study.
Welin L; Wilhelmsen L; Björnberg A; Odén A
Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1143-9. PubMed ID: 19672841
[TBL] [Abstract][Full Text] [Related]
19. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
Saito Y; Morimoto T; Ogawa H; Nakayama M; Uemura S; Doi N; Jinnouchi H; Waki M; Soejima H; Sugiyama S; Okada S; Akai Y;
Diabetes Care; 2011 Feb; 34(2):280-5. PubMed ID: 21270185
[TBL] [Abstract][Full Text] [Related]
20. All-cause mortality following low-dose aspirin treatment for patients with high cardiovascular risk in remote Australian Aboriginal communities: an observational study.
Zhao Y; Jeyaraman K; Burgess P; Connors C; Guthridge S; Maple-Brown L; Falhammar H
BMJ Open; 2020 Jan; 10(1):e030034. PubMed ID: 31900264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
